Trial
NCT04341870
Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO
Phase IISUSPENDEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
—
Condition
COVID19
Intervention
Sarilumab
Why stopped
DSMB recommendation (futility)
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-05-06